Adipokines in chronic kidney disease - Fat tissue gives nephrologists a message

Peritoneal Dialysis International

Volumn 25, Issue 4, 2005, Pages 340-342

  Heimbürger, Olof ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CREATININE; CYTOKINE; GLUCOSE; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; ENERGY METABOLISM; GLUCOSE METABOLISM; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID METABOLISM; MORTALITY; NONHUMAN; NOTE; OBESITY; PATHOGENESIS; PERITONEAL DIALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 23744433912     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500406     Document Type: Note

References (24)

1. Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005; 15:131-6.
2. Axelsson J, Qureshi AR, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80:1222-9.
3. Stenvinkel P, Chung S-H, Heimbürger O, Lindholm B. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001; 21(Suppl 3):S157-62.
4. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82:4196-200.
5. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectih, correlates with thiazolidedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279:12152-62.
6. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamato Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-9.
7. Rajala MW, Scherer PE. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144:3765-73.
8. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16:1091-8.
9. Zoccali F, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino L, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13:134-41.
10. Ouchi N, Kihara S, Arita Y, Okamato Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signalling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
11. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type-2 diabetes mellitus. Lancet 2003; 361:226-8.
12. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20:129-34.
13. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, Hoff C, et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2003; 65:274-81.
14. Díez JJ, Iglesias P, Fernández-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62:242-9.
15. Bakkaloglu SA, Buyan N, Funahashi T, Pasaoglu H, Elhan AH, Hasanoglu E, et al. Adiponectin levels and atherosclerotic risk factors in pediatric chronic peritoneal dialysis patients. Perit Dial Int 2005; 25:357-61.
16. Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukomoto M, Emoto M, et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005; 54:330-4.
17. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8:1423-30.
18. Stenvinkel P, Lindholm B, Lönnqvist F, Katzarski K, Heimbürger O. Increases in serum leptin during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-9.
19. Patel SD, Rajala MW, Rosetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304:1154-8.
20. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-12.
21. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPARg activators. Biochem Biophys Res Commun 2003; 300:472-6.
22. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42:62-6.
23. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111:932-9.
24. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005; 307:366-7.